FIGURES AND TABLES
FROM:
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)
A Mayer, S K Sharma, B Tolner, N P Minton, D Purdy, P Amlot, G Tharakan, R H J Begent and K A Chester
BACK TO ARTICLE
Figure 1.
In the first stage of ADEPT, the intravenously administered antibody–enzyme fusion protein MFECPHis is allowed to localise in the tumour. In the second stage, prodrug ZD2767P, based on a bis-iodo-phenol mustard is given after clearance of enzyme from the circulation. CP cleaves the glutamate moiety to generate the active drug ZD2767D.
Full figure and legend (79K)
Figure 2.
Model of CP showing the discontinuous CM79-identified epitope (region 1 residues 157–163: KEYGVRD coloured in blue, region 2 residues 412–415 coloured in red). The graphic representation was produced with MOLMOL (Koradi et al, 1996).
Full figure and legend (179K)
Figure 3.
Schematic representation of the variants of MFE-CP. Panel A illustrates the genetic constructs of the fusion proteins expressed in E. coli after transfection with pPM331 (MFECP) and pDP161 (MFEdmCP), panel B the fusion proteins expressed in P. pastoris with a C-terminal His-tag after transfection with pPIC001 (MFECPHis) and pPIC002 (MFEdmCPHis).
Full figure and legend (73K)
Figure 4.
(A) SDS – PAGE and (B) Western blot of fusion proteins expressed in E. coli (1) molecular weight markers (2) MFECP (3) MFEdmCP. (C) SDS – PAGE and (D) Western blot fusion proteins expressed in P. pastoris (4) MFECPHis (5) MFEdmCPHis (6) molecular weight markers. Major band representing fusion proteins indicated by arrow.
Full figure and legend (103K)
Figure 5.
(A) Inhibition of binding of biotinylated CM79 antibody by sera of patients after administration of MFECPHis and A5CP. Binding of CM79 antibody in immunised sera was compared to CM79 antibody binding in normal human serum. Statistical comparison of the reduction of CM79 antibody binding after treatment with A5CP with the reduction of CM79 antibody binding after treatment with MFECPHis was significant (P=0.00003 for the comparison of all available sera after administration of MFECPHis and A5CP; P=0.023 for the comparison of HACA-positive sera only, unpaired Student's t-test). (B) Results were confirmed on CP-coated plates (P=0.0001 for the comparison of all available sera after administration of MFECPHis and A5CP, P=0.03 for the comparison of HACA-positive sera only, unpaired Student's t-test). Bars indicate standard deviation.
Full figure and legend (146K)
Figure 6.
Anti-CP antibody formation in mice after 50 
g MFECPHis (A), MFEdmCPHis (B) and A5CP (C) i.p. every 14 days for four doses. Individual bars represent mice with measurable anti-CP antibodies in each group of eight mice. Comparison of the number of injections prior to a measurable anti-CP antibody response showed no statistically significant difference between groups injected with MFECPHis and MFEdmCPHis (P=0.203; Fisher's exact test), while comparison of the groups immunised with A5CP and MFECPHis showed a statistical trend indicating that injections could be repeated more frequently after MFECPHis compared to A5CP (P=0.077; Fisher's exact test).
Figure 7.
HACA formation in patients 42 days after single administration of MFECPHis, each bar represents an individual patient, the dashed line indicates the cutoff for HACA positive sera. Three standard deviations were added to the mean of a pool of pretreatment sera diluted 1/100 to give the cutoff for HACA-positive sera.
Full figure and legend (72K)
